Last updated date
ABOUT THIS STUDY
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of PF-06480605 in subjects with moderate to severe ulcerative colitis.
Surgery Center of Aventura
Aventura, Florida, 33180, United States
Females and Males
- Male or female subjects between ≥ 18 and ≤ 75 years of age at the time of informed consent
- Male subjects able to father children and female subjects of childbearing potential must agree to use two highly effective methods of contraception throughout the study and until the Week 26 visit
- Diagnosis of ulcerative colitis (UC) for ≥ 4 months
- Must have inadequate response to, loss of response to, or intolerance to at least one conventional therapy for ulcerative colitis such as: Steroids; Immunosuppressants (AZA, 6-MP, or MTX); Anti TNF inhibitors (eg, infliximab, adalimumab, or golimumab); Anti-integrin inhibitors (eg, vedolizumab).
- Subjects currently receiving the following treatment are eligible provided they have been on stable doses of Oral 5
- ADA or sulfasalazine for at least 4 weeks prior to baseline; oral corticosteroids stable dose for at least 2 weeks prior to baseline; 6-MP or AZA stable dose for 8 weeks prior to baseline.
Diagnosis of indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic colitis or Crohn's Disease. Subjects with clinical findings suggestive of Crohn's disease (eg, fistulae, granulomas on biopsy) are also excluded.
- Subjects with colonic dysplasia or neoplasia, toxic megacolon, primary sclerosing cholangitis, known colonic stricture, history of colonic or small bowel stoma, history of colonic or small bowel obstruction or resection
- Known history of HIV based on documented history with positive serological test, or positive HIV serologic test at screening
- Presence of a transplanted organ
- Cancer or history of cancer or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell or squamous cell carcinoma that has been treated with no evidence of recurrence);
- Acute coronary syndrome (eg., myocardial infarction, unstable angina pectoris); - Any history of cerebrovascular disease within 24 weeks before screening;
- Class III or Class IV heart failure
- Prior evidence of liver injury or toxicity due to methotrexate
- Subjects receiving the following therapies within the designated time period:
- > 9 mg/day of oral budesonide or >20 mg/day prednisone or equivalent within 2 weeks prior to baseline
- IV, IM (parenteral), or topical (rectal) treatment of 5-ASA or corticosteroid enemas/suppositories within 2 weeks prior to baseline
- Biologics including anti-TNF inhibitors as described: Infliximab, Adalimumab, or Golimumab within 8 weeks prior to baseline
- Anti-integrin inhibitors (eg, vedolizumab) within 12 weeks prior to baseline
- Other investigational procedures or products, or live attenuated vaccine within 30 days prior to baseline.
- Current or history (within 2 years) of serious psychiatric disease or alcohol or drug abuse.
A placebo is not used in this trial
Follow up: 3 months
Screening: Up to 6 weeks
Treatment: 12 weeks
Follow up: 5 visits
Screening: Up to 2 visits
Treatment: 7 visits
The study drug has not been approved yet.
Post-Trial Access to Study Drug
Keeping a diary
Vital signs and measurements
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Ulcerative ColitisEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
Ulcerative ColitisTITRATE (inducTIon for acuTe ulceRATivE Colitis)
Ulcerative ColitisTofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study
- Chapel Hill, North Carolina
Ulcerative ColitisA Fasting Mimicking Diet on Ulcerative Colitis Patients Undergoing Tofacitinib Induction
- Miami, Florida
- Miami, Florida